mesoestetic® Pharma Group continues to grow in 2023. The Catalan company dedicated to cosmetics and aesthetic medicine has closed the 2023 financial year with a turnover of 67.8 million euros, 6.7% more than in 2022, as reported by the company in a press release.
The pharmaceutical laboratory based in Viladecans (Barcelona) forecasts a turnover of 84 million euros in 2024, a 24% increase, thus consolidating the growth achieved in recent years. In 2023, mesoestetic® has created 10 new jobs and expects to create 12 more in 2024.
The company has an international presence in 109 countries, accounting for 89% of the company's turnover, which certifies the importance of foreign business, especially in the European market, the Middle East and other countries such as China, Australia and Thailand.
In 2023, mesoestetic made an investment of 10 million euros to expand its corporate headquarters in Viladecans, which in the words of the founder, Joan Carles Fonts, was a clear and competitive commitment of the company: "We are committed to talent and the generation of our own knowledge in scientific research. We want to be at the forefront of excellence in aesthetic medicine treatments," says Font. Last year, the company allocated more than 40% of the previous year's annual profits to R&D&I, in order to continuously search for new innovative solutions. 450,000 euros were also invested with a view to becoming more sustainable. This amount was earmarked for the installation of solar panels to establish a photovoltaic installation for self-consumption and reduced CO2 per unit sold by 28%.
mesoestetic® is the only company in the sector in Spain authorised to produce cross-linked hyaluronic acid injectables (fillers), one of the most widely used product families in aesthetic medicine. In addition, the pharmaceutical laboratory already has 3 exclusive patents, and one more in the registration process, which have been applied to anti-ageing and depigmentation solutions, where the company is a world leader.